<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kosmidis, P.</style></author><author><style face="normal" font="default" size="100%">Mylonakis, N.</style></author><author><style face="normal" font="default" size="100%">Nicolaides, C.</style></author><author><style face="normal" font="default" size="100%">Kalophonos, C.</style></author><author><style face="normal" font="default" size="100%">Samantas, E.</style></author><author><style face="normal" font="default" size="100%">Boukovinas, J.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author><author><style face="normal" font="default" size="100%">Skarlos, D.</style></author><author><style face="normal" font="default" size="100%">Economopoulos, T.</style></author><author><style face="normal" font="default" size="100%">Tsavdaridis, D.</style></author><author><style face="normal" font="default" size="100%">Papakostas, P.</style></author><author><style face="normal" font="default" size="100%">Bacoyiannis, C.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2002</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2002</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036729263&amp;doi=10.1200%2fJCO.2002.12.112&amp;partnerID=40&amp;md5=0063e1f499f383de92be350b320098cd</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">3578 - 3585</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Purpose: We conducted this randomized study comparing the activity and toxicity of paclitaxel and gemcitabine (PG) and paclitaxel and carboplatin (PC) combinations for the treatment of advanced non-small-cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naive patients were randomized to paclitaxel 200 mg/m2 on day 1 plus either carboplatin at an area under the concentration-time curve of 6 on day 1 (group A) or gemcitabine 1,000 mg/m2 on days 1 and 8 (group B) every 3 weeks. A retrospective cost analysis was conducted using Student's t test to compare independent samples between groups. Results: A total of 509 patients (group A, 252 patients; group B, 257 patients) were enrolled; all characteristics were well balanced. The median survival time was 10.4 months (95% confidence interval [CI], 8.8 to 12 months) for group A and 9.8 months (95% CI, 8.0 to 11.7 months) for group B (P = .32). Respective 1-year survival rates were 41.7% and 41.4%. The response rate for group A was 28.0% (2% complete response [CR], 26% partial response [PR] [95% CI, 22% to 34%]), and the response rate for group B was 35.0% (5% CR, 30% PR) [95% CI, 29% to 41%]) (P = .12). Toxicity was mild. Grades 3/4 neutropenia, thrombocytopenia, and anemia for groups A and B were seen in 15% and 15%, 2% and 1%, and 5% and 2%, respectively. The mean total cost (outpatient clinic visits plus chemotherapy drug fee) for group A (€ 7,612.64) versus group B (€ 7,484.77) was not statistically significant (P &amp;lt; .66). Conclusion: The PG combination is as equally active and well tolerated as the PC combination in patients with advanced NSCLC. © 2002 by American Society of Clinical Oncology.</style></abstract><issue><style face="normal" font="default" size="100%">17</style></issue><notes><style face="normal" font="default" size="100%">Cited By :240Export Date: 21 February 2017</style></notes></record></records></xml>